Trial Profile
A Phase 1/1b Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors AADi; Aadi Bioscience
- 27 Jan 2023 Status changed from active, no longer recruiting to completed.
- 22 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.